Form 8-K · Current Report · Filed 2024-06-05
Apellis Pharmaceuticals Holds Annual Meeting with Director Elections and Audit Approval
Apellis Pharmaceuticals, Inc. held its Annual Meeting of Stockholders on June 5, 2024, where stockholders elected two new class I directors, ratified the appointment of Deloitte & Touche LLP as the independent auditor, and approved an advisory vote on executive compensation. Paul Fonteyne and Stephanie Monaghan O'Brien were elected as directors with 98,837,712 and 80,481,023 votes respectively. Deloitte & Touche LLP was ratified as the independent auditor with 109,564,727 votes in favor, and the advisory vote on executive compensation received 93,573,357 votes in favor.
- Filer
- Apellis Pharmaceuticals Inc. APLS · NASDAQ
- Filed
- Accession
- 0001193125-24-155179
- CIK
- 0001492422
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Submission of Matters to a Vote of Security Holders
Market reaction
Close before filing
$5.98
Next session
-0.9%
Since filing
-43.1%
Latest close
$3.40
What happened, not what will happen — closing prices around the filing date.
About Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medicines leveraging targeted inhibition of the complement system, a key component of the immune system that plays a crucial role in a variety of diseases. The company's flagship product, targeting diseases such as geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), highlights its commitment to addressing unmet medical needs with innovative treatments. Apellis Pharmaceuticals operates in the highly competitive pharmaceutical and biotechnology industry, collaborating with healthcare providers and research institutions to advance clinical treatment options. Headquartered in Waltham, Massachusetts, its contributions to medical science are significant, paving the way for advancements in immunology and therapy development. As a publicly traded entity, Apellis influences the healthcare sector by enhancing treatment paradigms and offering new hope for patients with chronic and debilitating conditions.
Never miss another APLS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.